~~<i id='ECCC024AF0'><strike id='ECCC024AF0'><tt id='ECCC024AF0'><pre id='ECCC024AF0'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

focus

knowledge

author：entertainment 2025-09-30 08:51:52 - browse：75

The FDA building -- First Opinion coverage from STAT — Adobe

The Food and Drug Administration on Thursday approved the first medicine developed specifically to treat the serious liver disease known as MASH.

The pill, called Rezdiffra, is made by Madrigal Pharmaceuticals.

Metabolic dysfunction-associated steatohepatitis, or MASH, is often associated with obesity. The accumulation of fat in the liver causes inflammation, which leads to fibrosis, or liver scarring, and can progress in more advanced stages to cirrhosis, cancer, and the need for a liver transplant.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Apple is now the first public company to be valued at $3 trillion
Next article： UCSF medical school apologizes for unethical prisoner experiments

hotspot

focus

explore

focus

hotspot

FDA'sPeterMarksJIMLOSCALZO/POOL/AFPviaGettyImagesWASHINGTON—TheFoodandDrugAdministrationneedsdozensm

WSS

SCOTUS to consider access to abortion pill mifepristone

Radiology is caught between AI's potential and concern for patients

Sanofi CEO defends move to abandon profit guidance, boost research

FDA needs staff influx to meet gene therapy needs, Marks says

A clever new way to fix Medicaid and graduate medical education

Spinal cord stimulation reduces pain in amputees, study finds

focus

knowledge

hotspot

Bright Health sells Medicare Advantage business to Molina

Supreme Court wrestles with OxyContin maker's bankruptcy deal

Alkermes shareholders re

Pregnancy discrimination could be enabled by AI

Anesthesiologist group: stop taking Ozempic before surgery

Congenital heart disease patients face new threat of heart failure

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

AstraZeneca CEO says participant had neurological symptoms, could be discharged today

Medicare details structure of new drug price negotiation program

Don't let 'shelved assets' gather dust. Make them into new lifesaving drugs

focus

FDA approves potent Eli Lilly obesity drug, Zepbound

Supreme Court wrestles with OxyContin maker's bankruptcy deal

Will General Catalyst be the first of many hospital takeovers?

Teach medical students about patients with intellectual disabilities

Congenital heart disease patients face new threat of heart failure

White House calls on federal agencies to crack down on AI abuses

explore

focus

hotspot

hotspot